Figure 5.

Clinical manifestations after VitD3-supplemented GP-SCIT. (a) Net ear thickness (mm) 2 h after GP injection performed after SCIT. Placebo-SCIT treated mice were plotted together as Controls (NC and PC). (b) Effective Dose (ED) of Methacholine, when the airway resistance reaches 3 cmH₂O s/mL. (c) Airway hyperactivity (AHR) was plotted as Resistance (R in cmH₂O s/mL) and as (d) Compliance (C in mL/cmH₂O). (e) Net levels of IL-5, IL-10, IL-13, and IFNγ in restimulated lung cell suspensions. Mean ± SEM (n = 8). NC Negative Control, PBS challenged; PC Positive Control, GP challenged; PCS PC with 300 nmol SAINT; PCD PC with 300 ng VitD3 in SCIT; GP 300kSQ GP in SCIT; GPS 300kSQ + 300 nmol SAINT; GPD 300kSQ + 300 ng VitD3; GP100DS 300kSQ + 100 ng VitD3 + 300 nmol SAINT; GP300DS 300kSQ + 300 ng VitD3 + 300 nmol SAINT. *P < 0.05, **P < 0.01, ***P < 0.001 compared to their own matching controls, unless otherwise specified.